Cargando…

Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points

BACKGROUND: Antipsychotics are recognised as a critical intervention for schizophrenia and bipolar disorder. Guidelines globally endorse the routine practice of antipsychotic monotherapy, at the minimum effective dose. Even in treatment-resistant schizophrenia, clozapine use is endorsed before combi...

Descripción completa

Detalles Bibliográficos
Autores principales: McMillan, Sara S, Jacobs, Sara, Wilson, Louise, Theodoros, Theo, Robinson, Gail, Anderson, Claire, Mihala, Gabor, Wheeler, Amanda J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390470/
https://www.ncbi.nlm.nih.gov/pubmed/28407747
http://dx.doi.org/10.1186/s12888-017-1295-1
_version_ 1782521467764736000
author McMillan, Sara S
Jacobs, Sara
Wilson, Louise
Theodoros, Theo
Robinson, Gail
Anderson, Claire
Mihala, Gabor
Wheeler, Amanda J
author_facet McMillan, Sara S
Jacobs, Sara
Wilson, Louise
Theodoros, Theo
Robinson, Gail
Anderson, Claire
Mihala, Gabor
Wheeler, Amanda J
author_sort McMillan, Sara S
collection PubMed
description BACKGROUND: Antipsychotics are recognised as a critical intervention for schizophrenia and bipolar disorder. Guidelines globally endorse the routine practice of antipsychotic monotherapy, at the minimum effective dose. Even in treatment-resistant schizophrenia, clozapine use is endorsed before combining antipsychotics. This aim of this study was to review antipsychotic polytherapy alone, high-dose therapy alone, polytherapy and high-dose prescribing patterns in adults discharged from an inpatient mental health unit at two time-points, and the alignment of this prescribing with clinical guideline recommendations. Additionally, associations with polytherapy and high-dose antipsychotic prescribing, including patient and clinical characteristics, were explored. METHODS: A retrospective clinical audit of 400 adults (200 patients at two different time-points) discharged with at least one antipsychotic. Preliminary findings and education sessions were provided to physicians between Cohorts. Outcomes (polytherapy alone, high-dose therapy alone, polytherapy and high-dose therapy) were compared between study Cohorts using chi-squared and rank-sum tests. Associations between outcomes and covariates were assessed using multivariable logistic regression. RESULTS: Most patients (62.5%) were discharged on a single antipsychotic within the recommended dose range. There was a clear preference for prescribing second generation antipsychotics, and in this respect, prescribing is aligned with current evidence-based guidelines. However, sub-optimal prescribing practices were identified for both Cohorts in relation to polytherapy and high-dose antipsychotic rates. Involuntary treatment, frequent hospitalisations and previous clozapine use significantly increased the risk of all three prescribing outcomes at discharge. CONCLUSIONS: In a significant minority, antipsychotic prescribing did not align with clinical guidelines despite increased training, indicating that the education program alone was ineffective at positively influencing antipsychotic prescribing practices. Further consideration should be given when prescribing antipsychotics for involuntary patients, people with frequent hospitalisations, and those who have previously trialled clozapine.
format Online
Article
Text
id pubmed-5390470
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53904702017-04-14 Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points McMillan, Sara S Jacobs, Sara Wilson, Louise Theodoros, Theo Robinson, Gail Anderson, Claire Mihala, Gabor Wheeler, Amanda J BMC Psychiatry Research Article BACKGROUND: Antipsychotics are recognised as a critical intervention for schizophrenia and bipolar disorder. Guidelines globally endorse the routine practice of antipsychotic monotherapy, at the minimum effective dose. Even in treatment-resistant schizophrenia, clozapine use is endorsed before combining antipsychotics. This aim of this study was to review antipsychotic polytherapy alone, high-dose therapy alone, polytherapy and high-dose prescribing patterns in adults discharged from an inpatient mental health unit at two time-points, and the alignment of this prescribing with clinical guideline recommendations. Additionally, associations with polytherapy and high-dose antipsychotic prescribing, including patient and clinical characteristics, were explored. METHODS: A retrospective clinical audit of 400 adults (200 patients at two different time-points) discharged with at least one antipsychotic. Preliminary findings and education sessions were provided to physicians between Cohorts. Outcomes (polytherapy alone, high-dose therapy alone, polytherapy and high-dose therapy) were compared between study Cohorts using chi-squared and rank-sum tests. Associations between outcomes and covariates were assessed using multivariable logistic regression. RESULTS: Most patients (62.5%) were discharged on a single antipsychotic within the recommended dose range. There was a clear preference for prescribing second generation antipsychotics, and in this respect, prescribing is aligned with current evidence-based guidelines. However, sub-optimal prescribing practices were identified for both Cohorts in relation to polytherapy and high-dose antipsychotic rates. Involuntary treatment, frequent hospitalisations and previous clozapine use significantly increased the risk of all three prescribing outcomes at discharge. CONCLUSIONS: In a significant minority, antipsychotic prescribing did not align with clinical guidelines despite increased training, indicating that the education program alone was ineffective at positively influencing antipsychotic prescribing practices. Further consideration should be given when prescribing antipsychotics for involuntary patients, people with frequent hospitalisations, and those who have previously trialled clozapine. BioMed Central 2017-04-13 /pmc/articles/PMC5390470/ /pubmed/28407747 http://dx.doi.org/10.1186/s12888-017-1295-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
McMillan, Sara S
Jacobs, Sara
Wilson, Louise
Theodoros, Theo
Robinson, Gail
Anderson, Claire
Mihala, Gabor
Wheeler, Amanda J
Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title_full Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title_fullStr Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title_full_unstemmed Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title_short Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points
title_sort antipsychotic prescribing for vulnerable populations: a clinical audit at an acute australian mental health unit at two-time points
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390470/
https://www.ncbi.nlm.nih.gov/pubmed/28407747
http://dx.doi.org/10.1186/s12888-017-1295-1
work_keys_str_mv AT mcmillansaras antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT jacobssara antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT wilsonlouise antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT theodorostheo antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT robinsongail antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT andersonclaire antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT mihalagabor antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints
AT wheeleramandaj antipsychoticprescribingforvulnerablepopulationsaclinicalauditatanacuteaustralianmentalhealthunitattwotimepoints